Janssen Biotech Inc.

09/16/2024 | Press release | Distributed by Public on 09/16/2024 07:15

Neoadjuvant TAR 200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle invasive bladder cancer